The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (Bev)-based therapy for patients (pts) with colorectal cancer (CRC): McGill University and Segal Cancer Centre experience.
D. W. Wasserman
No relevant relationships to disclose
N. Bouganim
No relevant relationships to disclose
G. Batist
No relevant relationships to disclose
P. Metrakos
No relevant relationships to disclose
P. Chaudhury
No relevant relationships to disclose
M. Hassanain
No relevant relationships to disclose
P. Kavan
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche